Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE told to evaluate all new drugs

  • Comment
The NHS drug regulator for England has been told that it must speed up its guidance process and consider all new treatments by an influential committee of MPs.

The Commons Health Select Committee said the National Institute for Clinical Excellence (NICE) should place more emphasis on ruling out the use of older treatments, which may be clinically outdated and not cost effective.

NICE should also take into account the wider impact on society of its recommendations, the committee added in its latest report, published today.

Responding to the report, NICE chairperson, professor Sir Michael Rawlins, said: ‘Perhaps the most significant recommendation is that we should consider all new drugs as they become available.

‘We will need to work closely with our stakeholders and the Department of Health to discuss the feasibility of achieving this,’ he said.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs